Literature DB >> 31707291

Non-operative management of spinal metastases: A prognostic model for failure.

Andrew J Schoenfeld1, Joseph H Schwab2, Marco L Ferrone3, Justin A Blucher3, Tracy A Balboni4, Lauren B Barton3, John H Chi5, James D Kang3, Elena Losina3, Jeffrey N Katz3.   

Abstract

OBJECTIVES: To describe patient-specific characteristics associated with non-operative failure leading to surgery. PATIENTS AND METHODS: We conducted a retrospective review of patients treated for spinal metastases from 2005 to 2017. We deemed patients as failures if they were treated non-operatively and then received a surgical intervention within one year of starting a non-operative regimen. We used multivariable Poisson regression to identify factors associated with non-operative failure. We conducted internal validation using bootstrapping with 1000 replications.
RESULTS: We identified 1205 patients with spinal metastases, of whom 834 were initially treated non-operatively and constituted the analytic sample. Of these 77 (9%) went on to have surgery within 1-year of presentation and were deemed non-operative treatment failures. We identified vertebral body collapse and/or pathologic fracture (adjusted Risk Ratio [RR] 1.75; 95% Confidence Interval [CI] 1.11, 2.76) and neurologic signs or symptoms at presentation (RR 1.90; 95% CI 1.19, 3.03) as factors independently associated with an increased risk of non-operative failure. Platelet-lymphocyte ratio >155, a marker for inflammatory state, was also associated with an increased risk of failure (RR 2.32; 95% CI 1.15, 4.69). Failure rates among those with 0, 1, 2 or all three of these risk factors were 5%, 7%, 12% and 20%, respectively (p = 0.004).
CONCLUSION: We found that 9% of patients with spinal metastases initially treated non-operatively received surgery within 1-year of commencing care. The likelihood of surgery increased with the number of risk factors. These results can be used in counseling and shared decision making at the time of initial presentation.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ambulatory function; Non-operative treatment; Prognosis; Spinal metastases; Surgery; Survival

Mesh:

Substances:

Year:  2019        PMID: 31707291      PMCID: PMC6949394          DOI: 10.1016/j.clineuro.2019.105574

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  24 in total

Review 1.  Metastatic disease in the thoracic and lumbar spine: evaluation and management.

Authors:  Peter S Rose; Jacob M Buchowski
Journal:  J Am Acad Orthop Surg       Date:  2011-01       Impact factor: 3.020

2.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

3.  Predictive Value of Six Prognostic Scoring Systems for Spinal Bone Metastases: An Analysis Based on 1379 Patients.

Authors:  Laurens Bollen; Christine Wibmer; Yvette M Van der Linden; Willem Pondaag; Marta Fiocco; Wilco C Peul; Corrie A M Marijnen; Rob G H H Nelissen; Andreas Leithner; Sander P D Dijkstra
Journal:  Spine (Phila Pa 1976)       Date:  2016-02       Impact factor: 3.468

4.  Predicting survival for metastatic spine disease: a comparison of nine scoring systems.

Authors:  A Karim Ahmed; C Rory Goodwin; Amir Heravi; Rachel Kim; Nancy Abu-Bonsrah; Eric Sankey; Daniel Kerekes; Rafael De la Garza Ramos; Joseph Schwab; Daniel M Sciubba
Journal:  Spine J       Date:  2018-03-19       Impact factor: 4.166

5.  Effect of Surgery on Quality of Life of Patients with Spinal Metastasis from Non-Small-Cell Lung Cancer.

Authors:  Yu Tang; Jintao Qu; Juan Wu; Huan Liu; Tongwei Chu; Jianru Xiao; Yue Zhou
Journal:  J Bone Joint Surg Am       Date:  2016-03-02       Impact factor: 5.284

6.  Complications and reoperations after surgery for 647 patients with spine metastatic disease.

Authors:  Nuno Rui Paulino Pereira; Paul T Ogink; Olivier Q Groot; Marco L Ferrone; Francis J Hornicek; C N van Dijk; J A M Bramer; Joseph H Schwab
Journal:  Spine J       Date:  2018-06-01       Impact factor: 4.166

7.  Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study.

Authors:  Ryckie G Wade; Alyss V Robinson; Michelle C I Lo; Claire Keeble; Maria Marples; Donald J Dewar; Marc D S Moncrieff; Howard Peach
Journal:  Ann Surg Oncol       Date:  2018-07-31       Impact factor: 5.344

8.  Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases.

Authors:  Quirina C B S Thio; W Alexander Goudriaan; Stein J Janssen; Nuno Rui Paulino Pereira; Daniel M Sciubba; Rachel P Rosovksy; Joseph H Schwab
Journal:  Br J Cancer       Date:  2018-08-17       Impact factor: 7.640

9.  Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer.

Authors:  Uiju Cho; Hong Sik Park; So Young Im; Chang Young Yoo; Ji Han Jung; Young Jin Suh; Hyun Joo Choi
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

Review 10.  The Role of Prognostic Scoring Systems in Assessing Surgical Candidacy for Patients With Vertebral Metastasis: A Narrative Review.

Authors:  John Tristan Cassidy; Joseph F Baker; Brian Lenehan
Journal:  Global Spine J       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.